Holen Sie sich die Stockscreener-App
7.41
0.67%
-0.05
Handel nachbörslich:
7.41
Schlusskurs vom Vortag:
$7.46
Offen:
$7.51
24-Stunden-Volumen:
1.78M
Relative Volume:
0.96
Marktkapitalisierung:
$2.50B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$-184.45M
KGV:
-10.89
EPS:
-0.6805
Netto-Cashflow:
$229.23M
1W Leistung:
-7.03%
1M Leistung:
-0.27%
6M Leistung:
-15.12%
1J Leistung:
+14.53%
1-Tages-Spanne:
$7.41
$7.65
1-Wochen-Bereich:
$7.145
$8.01
52-Wochen-Spanne:
$6.29
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Vergleichen Sie AMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
7.41 | 2.50B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Amneal Pharmaceuticals to add 200 jobs at its Brookhaven factory - Newsday
Does Amneal (AMRX) Have the Potential to Rally 54.16% as Wall Street Analysts Expect? - Nasdaq
Decoding Amneal Pharmaceuticals Inc (AMRX): A Strategic SWOT Ins - GuruFocus
Amneal Pharmaceuticals Approves Key Proposals at Annual Meeting - TipRanks
Here is Why Growth Investors Should Buy Amneal (AMRX) Now - Yahoo Finance
Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals Stock? - Yahoo Finance
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal - GlobeNewswire
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced ... - Bluefield Daily Telegraph
Amneal Pharmaceuticals, Inc. and Apiject Systems, Corp. to Expand Sterile and Blow-Fill-Seal Capabilities for Advanced Pharmaceutical Manufacturing in the U.S - marketscreener.com
Amneal Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Amneal targets $3B-$3.1B in 2025 revenue with strong growth drivers - MSN
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Call Highlights: Strong Growth and Strategic ... By GuruFocus - Investing.com Canada
Amneal Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Amneal: Q1 Earnings Snapshot - MySA
Amneal Q1 2025 slides: Revenue up 5%, EPS surges 50% amid strategic shift - Investing.com Nigeria
Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson's Drug But Q1 Earnings Are Mixed - Benzinga
Earnings call transcript: Amneal Pharmaceuticals Q1 2025 beats EPS forecasts - Investing.com Nigeria
Amneal Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:AMRX) - Seeking Alpha
Amneal (AMRX) Reports Strong Start in 2025 Despite Missing Reven - GuruFocus
Amneal Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Amneal Pharmaceuticals Q1 2025: Revenue Miss but Profit Beats ExpectationsNews and Statistics - IndexBox
Amneal Pharma A earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
Amneal Pharma Swings To Profit In Q1, Beats Estimates; Affirms FY25 Guidance - Nasdaq
Amneal Reports First Quarter 2025 Financial Results - BioSpace
Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates - Yahoo Finance
Amneal Pharmaceuticals Reports Strong Q1 2025 Financial Results - TipRanks
Amneal (AMRX) Reports Strong Start in 2025 Despite Missing Revenue Estimates | AMRX Stock News - GuruFocus
Amneal Pharmaceuticals misses revenue estimates, stock falls 3% By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise; 2025 Outlook Affirmed - marketscreener.com
Amneal (NASDAQ:AMRX) Misses Q1 Sales Targets, Stock Drops 11.3% - Yahoo Finance
Amneal Pharmaceuticals misses revenue estimates, stock falls 3% - Investing.com
(AMRX) Amneal Pharmaceuticals Forecasts Fiscal Year 2025 Adjusted EPS Range $0.65$0.70 - marketscreener.com
Earnings Flash (AMRX) Amneal Pharmaceuticals Posts Q1 Revenue $695.4M, vs. FactSet Est of $714.8M - marketscreener.com
Amneal (AMRX) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Despite recent sales, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders remain the largest stockholders with 49% ownership - simplywall.st
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
2 Reasons to Avoid AMRX and 1 Stock to Buy Instead - Yahoo Finance
Parkinson’s Disease Therapeutic Domain Projected to See Transformational Growth Across the 7MM During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Amneal Pharmaceutical LLC Issues a Nationwide Recall of Ropivacaine Hydrochloride Injection, USP 500mg/100mL, Due to the Potential Presence of Particulate Matter - usrecallnews.com
Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years - Yahoo Finance
Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
1.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):